来源: Pharmaceutical Technology
Alumis will begin trading on Nasdaq on 28 June. Image credit: Shutterstock / Stuart Monk.
Hot on the heels of securing $259m in Series C financing three months ago, Alumis has raised a further $250m after revealing the pricing of its US initial public offering (IPO). The pricing is at the lower end of a previously announced price range in an SEC filing. The immunology company had originally expected proceeds of $274m in an IPO landscape that is reawakening following a lull over the past few years.
The $16 per share pricing values the company at around $902m, according to Reuters.
Alumis will begin trading on Nasdaq today [28 June], under the symbol ALMS. The offering is expected to close on 1 July.
See Also:Formation Bio secures $372m funds for AI-driven drug platform 来源: Pharmaceutical Technology
Capturing the genAI boom for drug development
来源: Pharmaceutical Technology
Alumis’ IPO closely follows a U-turn earlier this month taken by Telix Pharmaceuticals, which pulled the plug on plans for a Nasdaq listing. Telix, which was on course to raise $232m from the IPO, cited “current market conditions” as the reason behind abandoning these plans. The number of biotechs going public has steadily decreased after a boom in 2020 and 2021, although 2024 has seen an uptick in activity.